CNS Pharmaceuticals, Inc.
CNSP
$1.09
-$0.035-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.70M | 1.38M | 1.41M | 1.11M | 1.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.20M | 5.63M | 2.53M | 3.54M | 5.38M |
| Operating Income | -3.20M | -5.63M | -2.53M | -3.54M | -5.38M |
| Income Before Tax | -3.18M | -5.61M | -2.53M | -3.54M | -5.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.18M | -5.61M | -2.53M | -3.54M | -5.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.18M | -5.61M | -2.53M | -3.54M | -5.38M |
| EBIT | -3.20M | -5.63M | -2.53M | -3.54M | -5.38M |
| EBITDA | -3.20M | -5.63M | -2.53M | -3.54M | -5.38M |
| EPS Basic | -2.96 | -12.64 | -- | -- | -- |
| Normalized Basic EPS | -1.85 | -7.90 | -- | -- | -- |
| EPS Diluted | -2.96 | -12.64 | -- | -- | -- |
| Normalized Diluted EPS | -1.85 | -7.90 | -- | -- | -- |
| Average Basic Shares Outstanding | 1.07M | 443.60K | -- | -- | -- |
| Average Diluted Shares Outstanding | 1.07M | 443.60K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |